Cigna (CI) Downgraded by ValuEngine
CI has been the subject of a number of other reports. Zacks Investment Research raised Cigna from a hold rating to a buy rating and set a $208.00 target price for the company in a research report on Friday, January 4th. Morgan Stanley decreased their target price on Cigna from $304.00 to $299.00 and set an overweight rating for the company in a research report on Tuesday, February 5th. Credit Suisse Group reissued a buy rating and issued a $250.00 target price on shares of Cigna in a research report on Monday, January 7th. Barclays decreased their target price on Cigna from $220.00 to $207.00 and set an overweight rating for the company in a research report on Wednesday, April 17th. Finally, Stephens began coverage on Cigna in a research report on Monday, January 14th. They issued an overweight rating and a $251.00 target price for the company. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and thirteen have issued a buy rating to the company’s stock. The company currently has an average rating of Buy and an average target price of $230.47.
CI opened at $149.00 on Thursday. Cigna has a one year low of $141.95 and a one year high of $226.60. The stock has a market capitalization of $56.63 billion, a PE ratio of 10.48, a price-to-earnings-growth ratio of 0.73 and a beta of 0.71. The company has a current ratio of 0.42, a quick ratio of 0.42 and a debt-to-equity ratio of 0.96.
The business also recently disclosed a special dividend, which was paid on Wednesday, April 10th. Shareholders of record on Monday, March 11th were given a dividend of $0.04 per share. The ex-dividend date was Friday, March 8th. Cigna’s payout ratio is 0.28%.
In other news, insider Michael W. Triplett sold 9,148 shares of the firm’s stock in a transaction that occurred on Monday, February 11th. The stock was sold at an average price of $181.01, for a total value of $1,655,879.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Brian C. Evanko purchased 2,000 shares of Cigna stock in a transaction dated Monday, March 11th. The stock was acquired at an average cost of $163.40 per share, with a total value of $326,800.00. The disclosure for this purchase can be found here. Insiders have sold a total of 10,420 shares of company stock valued at $1,886,122 over the last ninety days. 0.80% of the stock is owned by insiders.
Institutional investors and hedge funds have recently bought and sold shares of the company. Clarfeld Financial Advisors LLC acquired a new stake in shares of Cigna in the 4th quarter valued at approximately $25,000. 1 North Wealth Services LLC purchased a new position in Cigna in the 4th quarter valued at approximately $25,000. Private Ocean LLC purchased a new position in Cigna in the 4th quarter valued at approximately $26,000. Delta Asset Management LLC TN purchased a new position in Cigna in the 4th quarter valued at approximately $28,000. Finally, Litman Gregory Asset Management LLC purchased a new position in Cigna in the 4th quarter valued at approximately $30,000. 88.31% of the stock is owned by institutional investors and hedge funds.
Cigna Company Profile
Cigna Corporation, a health service organization, provides insurance and related products and services in the United States and internationally. It operates through Integrated Medical, Health Services, International Markets, and Group Disability and Other segments. The Integrated Medical segment offers medical, pharmacy, dental, behavioral health and vision, health advocacy programs, and other products and services to insured and self-insured clients; Medicare Advantage, Medicare Supplement, and Medicare Part D plans to Medicare-eligible beneficiaries, as well as Medicaid plans; and health insurance coverage to individual customers on and off the public exchanges.
Recommended Story: What factors cause inflation to rise?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Cigna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cigna and related companies with MarketBeat.com's FREE daily email newsletter.